LogicBio Therapeutics

Kendall Square
United States

Tel: 781-771-5579

Email: contact@logicbio.com

Show jobs for this employer

About LogicBio Therapeutics

A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children’s Medical Research Institute in Sydney – the company’s core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company’s discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.
August 2015
Founders: Adi Barzel Ph.D., Mark Kay M.D. Ph.D. and Leszek Lisowski Ph.D.
President & CEO: Frederic Chereau

89 articles with LogicBio Therapeutics